N/A N=257 Compliance With Treatment For Patients With Hyperlipidemia
Hyperlipidemia
Primary: Percentage of Participants With Positive Response on Increased Motivation Using a Self-test at Month 12 — 36.2 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Smart Capsule for Automatic Adherence Monitoring
Medication Adherence
Primary: Medication Adherence — 88.1; 96.6; 94.4 percentage of doses taken (pill count)
N/A N=200 Does a Patient Education Video Augment Pelvic Floor Physical Therapy Compliance?
Patient Compliance · Pelvic Floor Disorders
Primary: Number of Participants With Completed PT Visits — 47; 50; 11; 21 Participants — p=0.17
N/A N=375 Observational Study On Compliance Of Statin Treatment Of Patients With High Blood Cholesterol Levels
Dyslipidemia
Primary: Percentage of Participants Who Were Compliant With Statin Treatment — 86.7 Percentage of participants
N/A N=50 Nexus Compliance Study
Obstructive Sleep Apnea
Primary: Compliance on CPAP — 6.58; 7.07; 6.72 Hours
N/A N=36 Patient-Assisted Compression in 3D - Impact on Image Quality and Workflow
Breast Cancer
Primary: Percentage of Acceptable Overall Image Quality — 30; 33; 3; 0 Participants
N/A N=245 Effect of Compliance Counseling on Brace Success in Patients With Idiopathic Scoliosis
Adolescent Idiopathic Scoliosis
Primary: Brace Progress Report (i.e. Informing the Patient How Often They Were Wearing the Brace Versus Not Informing the Patient) — 93; 78; 26; 29 participants
N/A N=67 Outcomes of Compliance With Brace Wear in Clubfoot
Clubfoot
Primary: Wear Rate Percentage (Number of Hours Per Day Brace Was Worn Out of the Recommended 24 Hours) — 91.7; NA; NA; 86.8 percentage of time worn
Phase 4 N=197 Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
Chronic Hepatitis C · Genotype 1
Primary: Treatment Duration Compliance Rate — 85.4; 83.8 Percentage of compliance — p=0.4864
Phase 4 N=154 Self-management of Low Molecular Weight Heparin Therapy
Thromboembolism
Primary: Drug Use Problems — 1.25; 0.86; 1.20; 1.17 scores on a scale
N/A N=124 Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA
Premature Infants
Primary: Number of Injections Per Patient Per Season — 3.8; 3.9; 4.0; 1.0 Injections administered
N/A N=29 Effect of Angulus on Patient-elevation Compliance
Ventilator Adverse Event · Ventilator Associated Pneumonia · Hospital Acquired Condition
Primary: Compliance to Head of Bed Elevation to 30 Degree or More. — 37.3; 32.4 percentage of time
N/A N=99 Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671)
Hepatitis C, Chronic · Hepatitis C
Primary: The Number of Participants Who Complete Treatment With PegIntron/Rebetol Therapy for Hepatitis C — 51; 32 Participants
N/A N=40 Assessing the Effectiveness and Safety of the ID-Cap System for Medication Monitoring and Adherence
Medication Adherence
Primary: Medication Adherence — 94.8; 82.8 percentage of doses taken
N/A N=270 Self-Management of Continuous Positive Airway Pressure Settings
Obstructive Sleep Apnea
Primary: Treatment Adherence — 2.1; 2.2 Hours per night
N/A N=401 SATisfaction and Adherence to COPD Treatment
Pulmonary Disease, Chronic Obstructive
Primary: The Patients' Satisfaction With Chronic Obstructive Pulmonary Disease (COPD) Medical Treatments During a 12-month Observation Period — 64.2; 66.2; 67.1; 75.8 Unit on Scale
N/A N=48 Auto Bilevel Adherence Following a Poor Initial Encounter With Continuous Positive Airway Pressure (CPAP)
Obstructive Sleep Apnea
Primary: Group Compliance of the Auto Bilevel Group Compared to the CPAP Group Measured by Average Nightly Use. — 284.7; 255.1 minutes/night — p=0.377
N/A N=294 Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)
Hepatitis C, Chronic · Hepatitis C
Primary: Number of Participants Who Are Triple-80 Compliant — 183 Participants
N/A N=20 Compass Device CVC Trial
Blood Pressure
Primary: Operator Satisfaction — 8 score on a scale
N/A N=29 Study Evaluating Flexitouch Plus With Connectivity on Compliance in 30 Patients With Breast Cancer-Related Lymphedema.
Breast Cancer Lymphedema
Primary: Compliance Measured as the Average Number of Treatments Per Week — 5.3; 5.2 treatments/week
Phase 4 N=262 Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia
Dyspepsia · Compliance · Depression
Primary: Compliance of Flupentixol-Melitracen — 44; 28; 31 participants
N/A N=31 Patient-Assisted Compression - Impact on Image Quality and Workflow
Breast Cancer
Primary: Number of Subjects With Acceptable Overall Clinical Image Quality for Patient-assisted (PA) and Technologist-controlled (TC) Image Sets — 30; 30 Participants
N/A N=58 Disease Management for Coronary Artery Patients
Patient Empowerment · Coronary Artery Disease
Primary: Compliance Questionnaire Scores of the Participants — 22.25; 22.53 score on a scale
N/A N=153 Non-compliance on Treatment Among Diabetic Students at Sohag University
Diabetes Mellitus, Type 1
Primary: Distribution of Participants Responses as Regards DSMQ Glucose Management Domain — 13; 56; 39; 45 Participants
N/A N=169 CPAP (Continuous Positive Airway Pressure) Study Educational Materials and Usage Feedback to Promote CPAP Adherence
Adherence
Primary: Nightly Adherence — 4.83; 5.82; 4.82; 4.60 hours
Phase 2 N=21 Feasibility of an Integrated Patient Care (IPC) System Using Daily Filling Pressures
Heart Failure
Primary: Characterize the Technical Feasibility of the Network Based IPC System — 72 percentage of days
N/A N=476 Behavioral Economic Strategies to Improve PRO Adherence
Cancer
Primary: PRO Adherence — 50.0; 56.9; 34.9 pct. assigned questionnaires completed
N/A N=34 Usability Validation of Patient Monitoring Device for Pressure Injury Prevention and Fall Detection
Pressure Ulcer · Pressure Injury · Falls Injury
Primary: Usability Validation of Masimo Centroid System — 34 Participants
N/A N=7 Patient-reported Monitoring of Symptoms and Spirometry Via the patientMpower Platform in Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Acceptability of patientMpower Platform From Patient & Healthcare Professional Perspective — 3; 1; 1; 4 Participants
N/A N=106 Wearable Technology to Reduce Risk of DVT and Increase Patient Compliance
Orthopedic Disorder
Primary: Compliance to Prescribed Use — 67.7; 83.3 percentage of prescribed use/24hr